Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).
- Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
- Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
- Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
- By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.